selegiline + tadalafil

Selegiline + tadalafil is a combination therapy investigated by the University of South Florida for the treatment of erectile dysfunction in male patients with Parkinson's disease who exhibit an incomplete response to tadalafil monotherapy. The combination consists of selegiline, a selective and irreversible monoamine oxidase-B (MAO-B) inhibitor, and tadalafil, a phosphodiesterase-5 (PDE5) inhibitor. Selegiline is traditionally used to manage motor symptoms in Parkinson's disease by increasing dopamine levels, while tadalafil is a standard treatment for erectile dysfunction. This investigational approach aims to address the high prevalence of sexual dysfunction in the Parkinson's population by leveraging the potential synergistic effects of central dopamine enhancement and peripheral vasodilation.

Other names

selegiline + tadalafilselegiline and tadalafil